Clinical data | |
---|---|
Trade names | Litfulo |
Other names | PF-06651600 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a624015 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG |
|
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C15H19N5O |
Molar mass | 285.351 g·mol−1 |
3D model (JSmol) | |
| |
|
Ritlecitinib (PF-06651600), sold under the brand name Litfulo, is a medication used for the treatment of severe alopecia areata (hair loss).[4] Ritlecitinib is a kinase inhibitor which inhibits Janus kinase 3 and tyrosine kinase.[4][7][8]
The most common side effects include headache, diarrhea, acne, rashes, eczema, fever, mouth ulcers, dizziness, shingles rash, and abnormal findings in some laboratory test results.[9]
Ritlecitinib was approved for medical use in the United States in June 2023,[4][9][10] in the European Union in September 2023,[5] and in Canada in February 2024.[2]
Ritlecitinib is indicated for the treatment of severe alopecia areata for individuals twelve years of age and older.[4][5]
The FDA approved ritlecitinib based on evidence from a clinical trial of 718 participants with severe alopecia areata.[9] The efficacy and safety of ritlecitinib were evaluated in a randomized, double-blind, placebo controlled trial in 718 participants twelve years of age and older with alopecia areata with ≥50% scalp hair loss, including alopecia totalis and alopecia universalis.[9] The trial randomized 130 participants to ritlecitinib 50 mg once daily, 131 participants to placebo, and 457 participants to other ritlecitinib dosing regimens.[9] The safety evaluation was also supported by two placebo-controlled trials in which 80 participants were randomized to ritlecitinib 200 mg once daily for four weeks followed by 50 mg once daily and 82 participants were randomized to placebo.[9] The trial was conducted at 128 sites in 18 countries in Argentina, Australia, Canada, Chile, China, Colombia, Czech Republic, Germany, Hungary, Japan, Republic of Korea, Mexico, Poland, Russian Federation, Spain, Taiwan, the United Kingdom, and the United States.[9]
The annual list price of a prescription is US$49,000.[11]
Intracellular (initiation) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (reception) |
| ||||||||||||||
Extracellular |
| ||||||||||||||
Unsorted |
|
Other dermatological preparations (D11) | |
---|---|
Anti-seborrheics | |
Skin lightening | |
Skin darkening | |
Anti-inflammatories | |
Alopecia treatments | |
Hair growth inhibitors | |
Others |
|